Less than two years after pumping $31 million into migraine play Labrys Biologics Inc., investors will see a front-loaded return in a takeout by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Teva is acquiring Labrys for $200 million in cash up front, plus up to $625 million in developmental milestones.